Published in PLoS One on August 12, 2014
Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal (2012) 5.65
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (2010) 4.52
NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood (1991) 4.30
Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem (2000) 2.15
Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood (1999) 1.83
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood (2011) 1.73
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66
History of the development of arsenic derivatives in cancer therapy. Oncologist (2001) 1.61
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell (2010) 1.60
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood (2011) 1.52
Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem (1997) 1.49
Curing APL through PML/RARA degradation by As2O3. Trends Mol Med (2011) 1.27
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood (2000) 1.23
Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol (2012) 1.15
Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol (2005) 1.13
Overview of peroxiredoxins in oxidant defense and redox regulation. Curr Protoc Toxicol (2011) 1.08
Imatinib: a review of its use in chronic myeloid leukaemia. Drugs (2007) 1.06
Peroxiredoxins, gerontogenes linking aging to genome instability and cancer. Genes Dev (2012) 1.04
The in vivo toxicity of hydroxyurea depends on its direct target catalase. J Biol Chem (2010) 0.99
Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol (1998) 0.98
Delicious poison: arsenic trioxide for the treatment of leukemia. Blood (1997) 0.93
Targeting peroxiredoxins against leukemia. Exp Cell Res (2012) 0.86
Arsenic trioxide (AT) is a novel human neutrophil pro-apoptotic agent: effects of catalase on AT-induced apoptosis, degradation of cytoskeletal proteins and de novo protein synthesis. Br J Haematol (2006) 0.86
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res (2003) 0.86
bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res (1994) 0.85
Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer (2009) 0.83
Catalase activity and arsenic sensitivity in acute leukemia. Leuk Lymphoma (2008) 0.83
Cells enriched for catalase are sensitized to the toxicities of bleomycin, adriamycin, and paraquat. J Biol Chem (1993) 0.82
Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion. Apoptosis (2013) 0.82
Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. J Cell Physiol (2011) 0.81
Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide. Exp Toxicol Pathol (2008) 0.77